News | Mammography | May 15, 2019

Managing Architectural Distortion on Mammography Based on MR Enhancement

Study results exhibited at 2019 ARRS Annual Meeting

Managing Architectural Distortion on Mammography Based on MR Enhancement

May 15, 2019 — High negative predictive values (NPV) in mammography architectural distortion (AD) without ultrasonographic (US) correlate or magnetic resonance imaging (MRI) enhancement suggests follow-up rather than biopsy may be safely performed, according to a new study. The study was presented at the American Roentgen Ray Society (ARRS) 2019 Annual Meeting, May 5-10 in Honolulu.

Management of MG-detected AD varies among practices when tomosynthesis-guided biopsy is not available. The study was conducted to evaluate outcomes of architectural distortion on mammography (MG) with or without a magnetic resonance (MR) correlate.

Unexplained architectural distortion on MG cases with subsequent MR were retrospectively reviewed by MG type, biopsy type and cancer results, cancer type, tumor grade and receptor status. Among the study group of 57 patients, the negative predictive value of MG AD without MR correlate or enhancement was 97.2 percent. Forty-four of 57 had MG AD without US correlate. Of 12 patients without US but with MR correlate, cancers (25 percent) were masses on MR, majority of benign findings (58.3 percent) were nonmass enhancement (NME), and RS/CSL (41.7 percent) was mass or NME. No MG AD without US or MR correlate was found to be cancer. The NPV of MG AD without US or MR correlate or enhancement was 100 percent.

The results indicate that follow-up rather than biopsy may be safely performed in cases of MG AD without US and MRI correlate or enhancement, reducing the need for intervention and lowering healthcare costs.

"With 3-D tomosynthesis widely incorporated in many practices, MG AD without US or MRI correlate poses a management dilemma to radiologists," author of the study Vandana Dialani, M.D. said. "This study is especially important for institutions which do not have tomo-guided biopsy capabilities and may revert to contrast imaging as a next step in managing MG AD. Our study shows that the NPV of MG AD without US correlate or MR enhancement was 100 percent and follow-up rather than biopsy may be considered."

For more information: www.arrs.org

Related Content

An image on Brigham and Women's Hospital's 7T MRI system

An image on Brigham and Women's Hospital's 7T MRI system. Image courtesy of Brigham and Women's Hospital

News | Magnetic Resonance Imaging (MRI) | November 13, 2019
November 13, 2019 — Increased immune system activity along the surface of the brain, or meningeal inflammation, may b
 Mammography doctor
News | Breast Imaging | November 12, 2019
November 12, 2019 — Geisinger has partnered with...
Radiographer Apollo Exconde with his Lego concept open MRI for patient education.

Radiographer Apollo Exconde with his Lego concept open MRI for patient education.

News | Patient Engagement | November 11, 2019
November 11, 2019 — Radiographer Apollo Exconde...
Image by Dr. Manuel González Reyes from Pixabay

Image by Dr. Manuel González Reyes from Pixabay 

News | SPECT Imaging | November 08, 2019
November 8, 2019 — Using ground-breaking technology, researchers at the...
This chest X-ray of a patient being treated for e-cigarette or vaping-associated lung injury shows lung opacities, densities and whitish cloud-like areas which are typically seen with unusual pneumonias, fluid in lungs or lung inflammation. Image courtesy of Intermountain Healthcare

This chest X-ray of a patient being treated for e-cigarette or vaping-associated lung injury shows lung opacities, densities and whitish cloud-like areas which are typically seen with unusual pneumonias, fluid in lungs or lung inflammation. Image courtesy of Intermountain Healthcare

News | Clinical Trials | November 08, 2019
November 8, 2019 — As the outbreak of lung injuries and deaths associated with e-cigarettes, or...
Unlike other technologies for imaging the placenta, pCASL MRI can distinguish maternal blood from fetal blood

Image courtesy of Pixabay

News | Clinical Trials | November 07, 2019
November 7, 2019 — A new imaging technique to track
Kubtec has made the Marcum Tech Top 40 (TT40) list of fastest growing technology companies in Connecticut
News | Radiology Business | November 06, 2019
November 6, 2019 — The Connecticut Technology Council (CTC) and...
The introduction of liquid helium free, high-end MRI systems by MR Solutions substantially reduces the environmental impact
News | Magnetic Resonance Imaging (MRI) | November 05, 2019
November 5, 2019 — Environmental impact is becoming a significant factor in the selection of suppliers even in precli